Compare Stocks → Now Open: Crypto emergency update (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BSTCNASDAQ:CBAYOTCMKTS:INVVYNASDAQ:PRVBNASDAQ:THOR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSTCBioSpecifics Technologies$88.53$88.47$42.00▼$89.15$650.25M0.2461,105 shsN/ACBAYCymaBay Therapeutics$32.48$32.09$7.26▼$32.50$3.73B0.324.11 million shs73 shsINVVYIndivior$21.85-1.8%$21.85$14.76▼$35.50$3.01B0.353,825 shs8,100 shsPRVBProvention Bio$24.98+3.1%$24.58$3.18▼$25.00$2.37B2.472.28 million shs9.12 million shsTHORSynthorx$67.99$67.99$11.05▼$71.90$2.20BN/A474,507 shsN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSTCBioSpecifics Technologies0.00%0.00%0.00%0.00%0.00%CBAYCymaBay Therapeutics0.00%0.00%0.00%+32.57%+224.15%INVVYIndivior0.00%0.00%0.00%0.00%+2.08%PRVBProvention Bio0.00%0.00%0.00%0.00%+2.21%THORSynthorx0.00%0.00%0.00%0.00%0.00%You’re invited: Biggest crypto event of 2024 (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACBAYCymaBay Therapeutics0.9065 of 5 stars2.00.00.04.70.02.50.6INVVYIndiviorN/AN/AN/AN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/AN/AN/AN/ATHORSynthorxN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSTCBioSpecifics TechnologiesN/AN/AN/AN/ACBAYCymaBay Therapeutics2.08Hold$28.65-11.79% DownsideINVVYIndiviorN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/ATHORSynthorxN/AN/AN/AN/ACurrent Analyst RatingsLatest PRVB, THOR, BSTC, CBAY, and INVVY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/29/2024CBAYCymaBay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$32.502/20/2024CBAYCymaBay TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$32.502/14/2024CBAYCymaBay TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/14/2024CBAYCymaBay TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$33.00 ➝ $32.502/14/2024CBAYCymaBay TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$25.00 ➝ $32.502/13/2024CBAYCymaBay TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral2/13/2024CBAYCymaBay TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold2/13/2024CBAYCymaBay TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$32.502/13/2024CBAYCymaBay TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$29.00 ➝ $32.502/13/2024CBAYCymaBay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSTCBioSpecifics Technologies$38.19M17.03$3.38 per share26.18$18.42 per share4.81CBAYCymaBay Therapeutics$31.07M119.92N/AN/A$2.58 per share12.59INVVYIndivior$791M3.81$1.15 per share18.94$1.45 per share15.07PRVBProvention Bio$12.90M183.54N/AN/A$1.40 per share17.84THORSynthorxN/AN/AN/AN/A$6.72 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSTCBioSpecifics Technologies$24.47M$3.3337.5117.60N/A47.43%14.81%14.46%N/ACBAYCymaBay Therapeutics-$105.37M-$0.97N/AN/AN/AN/A-50.72%-31.04%5/20/2024 (Estimated)INVVYIndivior$205M$1.0520.8112.00N/AN/AN/AN/AN/APRVBProvention Bio-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/ATHORSynthorx-$56.61M-$6.59N/AN/AN/AN/A-26.09%-24.62%N/ALatest PRVB, THOR, BSTC, CBAY, and INVVY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/28/2024Q4 2023CBAYCymaBay Therapeutics-$0.31-$0.35-$0.04-$0.35$0.42 million$0.06 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/ACBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/ATHORSynthorxN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSTCBioSpecifics TechnologiesN/A66.2466.24CBAYCymaBay TherapeuticsN/A10.9610.96INVVYIndiviorN/AN/AN/APRVBProvention Bio0.191.931.92THORSynthorxN/A18.8718.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSTCBioSpecifics Technologies60.34%CBAYCymaBay Therapeutics95.03%INVVYIndivior0.05%PRVBProvention Bio37.39%THORSynthorx66.12%Insider OwnershipCompanyInsider OwnershipBSTCBioSpecifics Technologies15.70%CBAYCymaBay Therapeutics7.00%INVVYIndiviorN/APRVBProvention Bio13.10%THORSynthorx53.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBSTCBioSpecifics Technologies77.35 millionN/ANot OptionableCBAYCymaBay Therapeutics101114.72 million106.69 millionOptionableINVVYIndivior800137.88 millionN/ANot OptionablePRVBProvention Bio8294.78 million82.37 millionNot OptionableTHORSynthorx4832.34 millionN/ANot OptionablePRVB, THOR, BSTC, CBAY, and INVVY HeadlinesSourceHeadlineDesign Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 21 at 4:55 PMDesign Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcriptinsidermonkey.com - March 20 at 3:52 PMEndeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial Officerfinance.yahoo.com - March 14 at 10:35 AMDupixent Redux? Synthekine, Sanofi Partner on Cytokine Therapiesgenengnews.com - January 29 at 6:12 PMSanofi pays Synthekine $40M to join preclinical push against vexing inflammatory targetfiercebiotech.com - January 29 at 8:12 AMEndeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. to Board of Directorsfinance.yahoo.com - December 19 at 10:44 AM‘We Have a Whole Ecosystem’: Barbara Borden Reflects on Blockbuster Horizon-Amgen Deal and Life Sciences Deals to Comelaw.com - November 2 at 3:05 PMPegenzileukin by Sanofi for Non-Small Cell Lung Cancer: Likelihood of Approvalpharmaceutical-technology.com - October 27 at 7:17 PMPegenzileukin by Sanofi for Squamous Cell Carcinoma: Likelihood of Approvalpharmaceutical-technology.com - June 10 at 10:29 AMPegenzileukin by Sanofi for Diffuse Large B-Cell Lymphoma: Likelihood of Approvalpharmaceutical-technology.com - June 10 at 10:29 AMMerck's $11B Prometheus Acquisition Brings IBD Drug & Precision ... - MedCity Newsnews.google.com - April 17 at 8:37 PMCapstan Therapeutics Appoints Justin Thacker as Chief Financial ... - Business Wirenews.google.com - March 22 at 5:01 PMCapstan Therapeutics Appoints Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D., as General Counsel - Yahoo Financenews.google.com - March 22 at 12:00 PMSanofi Goes All In For Type 1 Diabetes With Provention Buy - Scripnews.google.com - March 13 at 9:01 PMPegenzileukin by Sanofi for Head And Neck Cancer Squamous Cell Carcinoma: Likelihood of Approvalpharmaceutical-technology.com - March 3 at 10:18 PMBridge holds firm despite placebo beating drug in midphase ... - FierceBiotechnews.google.com - February 21 at 11:20 AMBiosimilar Interleukins Global Market Report 2023uk.finance.yahoo.com - February 16 at 10:03 AMReed Reaches End Of The Road As Sanofi R&D Chief - Scripnews.google.com - February 13 at 6:15 PM'Robust Ecosystem' Gives Strength to San Diego's Life Science Sector - San Diego Business Journalnews.google.com - February 6 at 4:43 PMGlobal Glucagon-like Peptide 1 (GLP-1) Market Research Report ... - WV Newsnews.google.com - January 30 at 9:54 AMBiosimilar Interleukins Market Size, Share And Growth Analysis For 2023-2032 - EIN Newsnews.google.com - January 19 at 1:28 PMGlobal Glucagon-like Peptide 1 Market: Analysis By Product, By Route of Administration, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027 - Yahoo Financenews.google.com - January 19 at 8:27 AMPD-1 and PDL-1 Inhibitors Market is forecast to reach a value of US ... - Medgadgetnews.google.com - January 19 at 8:27 AMResearchers, Industry Experts Discuss “The Future of mRNA ... - BioBuzznews.google.com - January 16 at 1:58 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBioSpecifics TechnologiesNASDAQ:BSTCBioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.CymaBay TherapeuticsNASDAQ:CBAYCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.IndiviorOTCMKTS:INVVYIndivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.Provention BioNASDAQ:PRVBProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.SynthorxNASDAQ:THORSynthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.